Sign In
Section Navigation
Common TitleATLAS-2M
Official Title Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
Phase Phase III
ClinicalTrials.gov NCT03299049
Treatments
Injectable cabotegravir and Rilpivirine

Injectable cabotegravir and Rilpivirine

Tradename:CabenuvaClass:Long-Acting Injectable Regimens
Categories Treatment-ExperiencedSwitch/SimplificationDual Therapy
Funding
IndustryJanssen
References
  • Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396:1994-2005.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.